ODI PHARMA AB Total Liabilities
ODI PHARMA AB total liabilities. Based on the latest financial reports, ODI PHARMA AB (6OD) has total liabilities worth €2.93 Million EUR (≈ $3.42 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of ODI PHARMA AB to measure how many days the company can operate on defensive assets alone.
Total Liabilities of ODI PHARMA AB (2022–2026)
Total liabilities of ODI PHARMA AB from 2022 to 2026. This chart illustrates how ODI PHARMA AB's total liabilities have evolved over time, based on quarterly financial data.
ODI PHARMA AB Competitors by Total Liabilities
The table below lists competitors of ODI PHARMA AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Elixirr International Plc
LSE:ELIX
|
UK | GBX108.56 Million |
|
Opthea Limited
NASDAQ:OPTEY
|
USA | $314.48 Million |
|
Damon Inc. Common Stock
NASDAQ:DMN
|
USA | $29.17 Million |
|
Casa Minerals Inc
V:CASA
|
Canada | CA$795.08K |
|
ROLLING OPTICS HOLDING AB
F:5LN
|
Germany | €29.62 Million |
|
Preecha Group Public Company Limited
BK:PRECHA
|
Thailand | ฿238.63 Million |
|
Marquee Resources Ltd
AU:MQR
|
Australia | AU$318.56K |
|
BIO-Key International Inc
NASDAQ:BKYI
|
USA | $3.20 Million |
Liability Composition Analysis (2022–2026)
This chart breaks down ODI PHARMA AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 6OD current and non-current assets.
Liquidity & Leverage Metrics
ODI PHARMA AB Total Liabilities Ratios Explained
ODI PHARMA AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ODI PHARMA AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ODI PHARMA AB (2022–2026)
The table below shows the annual total liabilities of ODI PHARMA AB from 2022 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | €2.93 Million ≈ $3.42 Million |
-30.09% |
| 2025-06-30 | €4.19 Million ≈ $4.89 Million |
-59.07% |
| 2024-06-30 | €10.23 Million ≈ $11.95 Million |
+82.18% |
| 2023-06-30 | €5.61 Million ≈ $6.56 Million |
+354.26% |
| 2022-06-30 | €1.24 Million ≈ $1.44 Million |
-- |
About ODI PHARMA AB
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products. ODI Pharma AB (publ) was founded in 2018 and is based in Stockholm, Sweden.